Prostate cancer stands as the most frequently diagnosed cancer among men in Europe, highlighting the urgent need for enhanced biomarker testing and precision oncology. Ongoing advancements depend on multidisciplinary collaboration and patient engagement. With genetic insights illuminating treatment paths, including those impacted by homologous recombination repair changes, establishing testing protocols is vital. However, varying healthcare systems across Europe introduce challenges in biomarker accessibility, necessitating standardized yet locally adapted workflows to ensure timely and effective patient care.
Newsletters
Receive the latest pathologist news, personalities, education, and career development – weekly to your inbox.